VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

This pediatric trial is testing atezolizumab — an immunotherapy drug that helps the immune system recognize and kill cancer — combined with standard chemotherapy in children and young people with solid tumors that have come back or stopped responding to prior treatment. The study covers a range of tumor types and aims to find safe, effective combinations. **You may be eligible if...** - You are a child or adolescent with a solid tumor that has relapsed or is refractory (not responding) after at least one prior treatment - Your cancer is not Hodgkin or non-Hodgkin lymphoma - If you have brain tumors or brain metastases, they must meet specific safety criteria - You and your guardian are able to give signed informed consent **You may NOT be eligible if...** - You have Hodgkin or non-Hodgkin lymphoma - You have cancer affecting critical brain structures (brainstem, midbrain, pons, cerebellum) or near the optic nerve - You have a history of leptomeningeal disease (cancer in the fluid around the brain and spine) Talk to your doctor to see if this trial is right for you.